Answers are grounded in this paper and cite their sources.
Case series evaluates sterile abscess formation during GnRH agonist therapy in adolescents, highlighting management strategies.
OBJECTIVES: Long-acting gonadotropin-releasing hormone agonists (GnRHa) are standard therapy for central precocious puberty (CPP). Depot formulations (triptorelin, leuprolide) ensure sustained release via biodegradable matrices. Rare sterile injection-site abscesses may impair drug absorption and efficacy, and evidence on management is limited. CASES PRESENTATION: Two patients (0.68 %) out of the 290 treated at our center with depot GnRHa between 2023 and 2025 developed recurrent culture-negative abscesses. They had normal immune workup and no IgE-mediated hypersensitivity or mastocytosis. Lesions caused pain, transient inflammation, and reduced efficacy. In one case, topical hydrocortisone butyrate 0.1 % for 5 days post-injection resolved abscesses and restored efficacy. CONCLUSIONS: Sterile abscesses are a rare but relevant complication of GnRHa therapy. Early recognition and exclusion of infection/allergy are key. Our experience with a patient who showed a good response to topical corticosteroids may be relevant in offering a conservative therapeutic option to treat the abscess lesion without discontinuing GnRHa therapy.
No takes yet. Share an insight, caveat, or question.
Sarli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: